📊 NXTC Key Takeaways
Is NextCure, Inc. (NXTC) a Good Investment?
NextCure demonstrates exceptional 252.6% YoY revenue growth indicating strong commercialization momentum; however, severe operating losses (-45.2% margin), negative free cash flow of -13.8M, and limited cash runway (~13 months at current burn rate) present material solvency risk. The clean balance sheet and zero debt provide some cushion, but the company must achieve profitability or secure additional funding before cash depletion.
Despite a debt-free balance sheet and strong liquidity, NextCure’s fundamentals are weak: deeply negative margins and ROE/ROA alongside heavy operating cash burn (~$49.6M) against ~$26M in cash imply a short runway and potential dilution. The sharp revenue jump is from a low base and may be nonrecurring, with profitability far from breakeven. Without durable revenue and substantial expense reduction, risk outweighs the improving top line.
NextCure, Inc. Key Strengths (NXTC)
- Exceptional revenue growth of 252.6% YoY indicating strong market traction and commercialization progress
- Fortress balance sheet with zero long-term debt and 15.2M cash, reducing financial leverage risk
- Excellent liquidity position with 4.61x current and quick ratios, ensuring near-term payment obligations
- Improving diluted EPS trend (+17.7% YoY) suggests operational efficiency gains despite unprofitability
- Debt-free capital structure
- Strong current and quick ratios (4.14x)
- Triple-digit revenue growth YoY
NXTC Stock Risks: NextCure, Inc. Investment Risks
- Severe cash burn with negative operating cash flow of -13.4M and free cash flow of -13.8M, indicating only ~13 months of runway at current rates
- Persistent unprofitability with -43.8% net margin and -45.2% operating margin despite revenue growth, signaling inability to scale efficiently
- Unclear path to profitability with no evidence of margin improvement trajectory as company scales
- Pharmaceutical sector execution risk: clinical development timelines, regulatory approval uncertainty, and competitive pressures remain unquantified
- Severe negative operating and net margins
- Large cash burn and negative FCF with limited cash runway
- High likelihood of external financing/dilution if losses persist
Key Metrics to Watch
- Quarterly operating cash flow trend and path to positive FCF
- Gross margin expansion as product mix matures and volumes increase
- Cash burn rate and updated runway estimates per quarterly filings
- Revenue growth sustainability and product-level profitability metrics
- Progress on clinical pipeline and regulatory milestones
- Quarterly operating cash burn/runway
- Revenue durability (recurring vs milestone)
NextCure, Inc. (NXTC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.61x current ratio provides a solid financial cushion.
NXTC Profit Margin, ROE & Profitability Analysis
NXTC vs Healthcare Sector: How NextCure, Inc. Compares
How NextCure, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NextCure, Inc. Stock Overvalued? NXTC Valuation Analysis 2026
Based on fundamental analysis, NextCure, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NextCure, Inc. Balance Sheet: NXTC Debt, Cash & Liquidity
NXTC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: NextCure, Inc.'s revenue has grown significantly by 253% over the 5-year period, indicating strong business expansion. The most recent EPS of $-23.88 indicates the company is currently unprofitable.
NXTC Revenue Growth, EPS Growth & YoY Performance
NXTC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | $22.4M | $9.7M | $-0.59 |
| Q2 2021 | $22.4M | -$2.8M | N/A |
| Q1 2021 | $22.4M | $9.2M | $0.33 |
| Q3 2020 | $1.6M | -$6.2M | N/A |
| Q2 2020 | $1.4M | -$2.8M | N/A |
| Q1 2020 | $1.4M | -$6.2M | $0.33 |
| Q3 2019 | $1.6M | -$5.0M | N/A |
| Q2 2019 | $1.4M | -$5.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NextCure, Inc. Dividends, Buybacks & Capital Allocation
NXTC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for NextCure, Inc. (CIK: 0001661059)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NXTC
What is the AI rating for NXTC?
NextCure, Inc. (NXTC) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NXTC's key strengths?
Claude: Exceptional revenue growth of 252.6% YoY indicating strong market traction and commercialization progress. Fortress balance sheet with zero long-term debt and 15.2M cash, reducing financial leverage risk. ChatGPT: Debt-free capital structure. Strong current and quick ratios (4.14x).
What are the risks of investing in NXTC?
Claude: Severe cash burn with negative operating cash flow of -13.4M and free cash flow of -13.8M, indicating only ~13 months of runway at current rates. Persistent unprofitability with -43.8% net margin and -45.2% operating margin despite revenue growth, signaling inability to scale efficiently. ChatGPT: Severe negative operating and net margins. Large cash burn and negative FCF with limited cash runway.
What is NXTC's revenue and growth?
NextCure, Inc. reported revenue of $22.4M.
Does NXTC pay dividends?
NextCure, Inc. does not currently pay dividends.
Where can I find NXTC SEC filings?
Official SEC filings for NextCure, Inc. (CIK: 0001661059) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NXTC's EPS?
NextCure, Inc. has a diluted EPS of $-1.87.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NXTC's fundamental grade?
Based on our AI fundamental analysis in May 2026, NextCure, Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NXTC stock overvalued or undervalued?
Valuation metrics for NXTC: ROE of -36.7% (sector avg: 15%), net margin of -43.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NXTC's AI grade for 2026?
Our dual AI analysis gives NextCure, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NXTC's free cash flow?
NextCure, Inc.'s operating cash flow is $-13.4M, with capital expenditures of $474.0K. FCF margin is -61.8%.
How does NXTC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -43.8% (avg: 12%), ROE -36.7% (avg: 15%), current ratio 4.61 (avg: 2).